110 related articles for article (PubMed ID: 17582546)
1. [Methylphenidate prescriptions in the city of Cologne: overrepresentation of privately insured patients. Results of an analysis based on prescription data].
Bessou H; Zeeb H; Puteanus U
Gesundheitswesen; 2007 May; 69(5):292-6. PubMed ID: 17582546
[TBL] [Abstract][Full Text] [Related]
2. [The use of methylphenidate in children: analysis of prescription usage based in routine data of the statutory health insurance bodies concerning drug prescriptions].
Schmidt-Troschke SO; Ostermann T; Melcher D; Schuster R; Erben CM; Matthiessen PF
Gesundheitswesen; 2004 Jun; 66(6):387-92. PubMed ID: 15206042
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of and change in the prescription of methylphenidate in Israel over a 2-year period.
Fogelman Y; Vinker S; Guy N; Kahan E
CNS Drugs; 2003; 17(12):915-9. PubMed ID: 12962530
[TBL] [Abstract][Full Text] [Related]
4. Changing Epidemiology of Methylphenidate Prescriptions in the Community: A Multifactorial Model.
Jaber L; Rigler S; Shuper A; Diamond G
J Atten Disord; 2017 Dec; 21(14):1143-1150. PubMed ID: 24776713
[TBL] [Abstract][Full Text] [Related]
5. Comorbidities in ADHD children treated with methylphenidate: a database study.
Kraut AA; Langner I; Lindemann C; Banaschewski T; Petermann U; Petermann F; Mikolajczyk RT; Garbe E
BMC Psychiatry; 2013 Jan; 13():11. PubMed ID: 23294623
[TBL] [Abstract][Full Text] [Related]
6. Attention-Deficit/Hyperactivity Disorder Medication Prescription Claims Among Privately Insured Women Aged 15-44 Years - United States, 2003-2015.
Anderson KN; Ailes EC; Danielson M; Lind JN; Farr SL; Broussard CS; Tinker SC
MMWR Morb Mortal Wkly Rep; 2018 Jan; 67(2):66-70. PubMed ID: 29346342
[TBL] [Abstract][Full Text] [Related]
7. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
[TBL] [Abstract][Full Text] [Related]
8. Patterns and profiles of methylphenidate use both in children and adults.
Pauly V; Frauger E; Lepelley M; Mallaret M; Boucherie Q; Micallef J
Br J Clin Pharmacol; 2018 Jun; 84(6):1215-1227. PubMed ID: 29512177
[TBL] [Abstract][Full Text] [Related]
9. Methylphenidate use for attention deficit hyperactivity disorder in northern Israel--a controversial issue.
Fogelman Y; Kahan E
Isr Med Assoc J; 2001 Dec; 3(12):925-7. PubMed ID: 11794916
[TBL] [Abstract][Full Text] [Related]
10. Use of medical services by methylphenidate-treated children in the general population.
Miller AR; Brehaut JC; Raina P; McGrail KM; Armstrong RW
Ambul Pediatr; 2004; 4(2):174-80. PubMed ID: 15018602
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
[TBL] [Abstract][Full Text] [Related]
12. Overlapping Prescriptions of Stimulants for Children and Adolescents With Attention-Deficit Hyperactivity Disorder.
Chen CY; Yeh HH; Fang SY; Wu EC; Chang IS; Lin KM
Psychiatr Serv; 2012 Oct; 63(10):1011-8. PubMed ID: 22911441
[TBL] [Abstract][Full Text] [Related]
13. Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan.
Wang LJ; Yang KC; Lee SY; Yang CJ; Huang TS; Lee TL; Yuan SS; Shyu YC
PLoS One; 2016; 11(8):e0161061. PubMed ID: 27518196
[TBL] [Abstract][Full Text] [Related]
14. Prescription of methylphenidate to children and youth, 1990-1996.
Miller AR; Lalonde CE; McGrail KM; Armstrong RW
CMAJ; 2001 Nov; 165(11):1489-94. PubMed ID: 11762572
[TBL] [Abstract][Full Text] [Related]
15. Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users.
Darredeau C; Barrett SP; Jardin B; Pihl RO
Hum Psychopharmacol; 2007 Dec; 22(8):529-36. PubMed ID: 17910020
[TBL] [Abstract][Full Text] [Related]
16. Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective.
Štuhec M; Locatelli I; Švab V
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):254-9. PubMed ID: 25803789
[TBL] [Abstract][Full Text] [Related]
17. Children's persistence with methylphenidate therapy: a population-based study.
Miller AR; Lalonde CE; McGrail KM
Can J Psychiatry; 2004 Nov; 49(11):761-8. PubMed ID: 15633854
[TBL] [Abstract][Full Text] [Related]
18. Impact of negative media publicity on attention-deficit/hyperactivity disorder medication in Taiwan.
Wang LJ; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Shyu YC
Pharmacoepidemiol Drug Saf; 2016 Jan; 25(1):45-53. PubMed ID: 26549311
[TBL] [Abstract][Full Text] [Related]
19. [Regional differences of ADHD diagnosis rates in health insurance data from 2005 to 2015 : Methodological considerations and results].
Grobe TG
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Dec; 60(12):1336-1345. PubMed ID: 29052741
[TBL] [Abstract][Full Text] [Related]
20. [Age- and Gender-specific Costs as Well as Drug Therapies of ADHD Patients].
Klora M; Zeidler J; Lublow D; Linder R; Verheyen F; von der Schulenburg JM
Gesundheitswesen; 2016 Jul; 78(7):e23-9. PubMed ID: 26695543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
